CN107484415B - 作为usp30抑制剂的1-氰基吡咯烷化合物 - Google Patents

作为usp30抑制剂的1-氰基吡咯烷化合物 Download PDF

Info

Publication number
CN107484415B
CN107484415B CN201680019213.6A CN201680019213A CN107484415B CN 107484415 B CN107484415 B CN 107484415B CN 201680019213 A CN201680019213 A CN 201680019213A CN 107484415 B CN107484415 B CN 107484415B
Authority
CN
China
Prior art keywords
cyanopyrrolidin
carboxamide
methyl
alkylene
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680019213.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107484415A (zh
Inventor
A·琼斯
M·肯普
M·斯托克利
K·吉布森
G·惠特洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1505429.9A external-priority patent/GB201505429D0/en
Priority claimed from GBGB1512829.1A external-priority patent/GB201512829D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Priority to CN202110132842.2A priority Critical patent/CN112707893B/zh
Publication of CN107484415A publication Critical patent/CN107484415A/zh
Application granted granted Critical
Publication of CN107484415B publication Critical patent/CN107484415B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CN201680019213.6A 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物 Active CN107484415B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110132842.2A CN112707893B (zh) 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1505429.9 2015-03-30
GBGB1505429.9A GB201505429D0 (en) 2015-03-30 2015-03-30 Novel compounds
GB1512829.1 2015-07-21
GBGB1512829.1A GB201512829D0 (en) 2015-07-21 2015-07-21 Novel compounds
PCT/GB2016/050851 WO2016156816A1 (en) 2015-03-30 2016-03-24 1-cyano-pyrrolidine compounds as usp30 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110132842.2A Division CN112707893B (zh) 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物

Publications (2)

Publication Number Publication Date
CN107484415A CN107484415A (zh) 2017-12-15
CN107484415B true CN107484415B (zh) 2021-01-29

Family

ID=55646790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680019213.6A Active CN107484415B (zh) 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物
CN202110132842.2A Active CN112707893B (zh) 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110132842.2A Active CN112707893B (zh) 2015-03-30 2016-03-24 作为usp30抑制剂的1-氰基吡咯烷化合物

Country Status (29)

Country Link
US (6) US10343992B2 (enExample)
EP (3) EP3943490A1 (enExample)
JP (3) JP6708661B2 (enExample)
KR (1) KR102578325B1 (enExample)
CN (2) CN107484415B (enExample)
AU (1) AU2016240033B2 (enExample)
BR (1) BR112017020900B1 (enExample)
CA (1) CA2976741C (enExample)
CO (1) CO2017011172A2 (enExample)
CY (1) CY1124170T1 (enExample)
DK (1) DK3277677T3 (enExample)
ES (1) ES2864950T3 (enExample)
HR (1) HRP20210791T2 (enExample)
HU (1) HUE054474T2 (enExample)
IL (1) IL254721B (enExample)
LT (1) LT3277677T (enExample)
MD (1) MD3277677T2 (enExample)
MX (1) MX373656B (enExample)
MY (1) MY188957A (enExample)
NZ (1) NZ736450A (enExample)
PL (1) PL3277677T3 (enExample)
PT (1) PT3277677T (enExample)
RS (1) RS61759B9 (enExample)
RU (1) RU2717238C2 (enExample)
SG (1) SG11201706542TA (enExample)
SI (1) SI3277677T1 (enExample)
SM (1) SMT202100287T1 (enExample)
WO (1) WO2016156816A1 (enExample)
ZA (1) ZA201705717B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AU2016240033B2 (en) * 2015-03-30 2020-04-16 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
EP3519385B1 (en) 2016-09-27 2020-11-18 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) * 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
JP7208931B2 (ja) * 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
KR102717600B1 (ko) * 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
CN112513036B (zh) * 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
US11572374B2 (en) * 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
ES2945834T3 (es) * 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
US20230143470A1 (en) * 2020-03-30 2023-05-11 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
CN111303128B (zh) * 2020-04-07 2020-10-27 苏州信诺维医药科技有限公司 一种多环类化合物、其制备方法及应用
EP4132925A1 (en) * 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
KR20230016674A (ko) * 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
JP2023529570A (ja) * 2020-06-04 2023-07-11 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
SI4161929T1 (sl) * 2020-06-08 2025-10-30 Mission Therapeutics Limited 1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kot zaviralec usp30 za uporabo pri zdravljenju mitohondrijske disfunkcije, raka in fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4267559A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
TWI861488B (zh) 2021-04-16 2024-11-11 美商基利科學股份有限公司 噻吩并吡咯化合物
CA3230800A1 (en) 2021-09-10 2023-03-16 Gilead Sciences, Inc. Thienopyrrole compounds
CA3234167A1 (en) 2021-10-11 2023-04-20 Joseph Fenton Lawler Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
EP4604947A2 (en) * 2022-10-19 2025-08-27 Ohio State Innovation Foundation Compositions and methods for preventing cardiomyopathy
TW202446368A (zh) * 2023-02-28 2024-12-01 美商賽堤爾醫療公司 經取代之吡咯啶及吡咯啶酮化合物
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2009129371A1 (en) * 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
KR100944301B1 (ko) * 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
WO2010074776A2 (en) 2008-06-16 2010-07-01 The University Of Tennessee Research Foundation Compounds for the treatment of cancer
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
AU2012326682B2 (en) * 2011-10-19 2016-02-18 Vivolux Ab Method for inhibition of deubiquitinating activity
MX394449B (es) 2012-01-12 2025-03-11 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
MX364438B (es) 2013-03-15 2019-04-26 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP6618120B2 (ja) 2014-08-06 2019-12-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AU2016240033B2 (en) * 2015-03-30 2020-04-16 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
CN107849013B (zh) 2015-07-14 2022-03-29 特殊治疗有限公司 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
EP3519385B1 (en) * 2016-09-27 2020-11-18 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2009129371A1 (en) * 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C;Dramane Laine等;《ACS Med. Chem. Lett.》;20101110;第2卷;第142-147页 *
Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L;Jean-Pierre Falgueyret等;《J. Med. Chem.》;20001207;第44卷;第94-104页 *

Also Published As

Publication number Publication date
MX373656B (es) 2020-04-02
BR112017020900A2 (pt) 2018-07-10
SMT202100287T1 (it) 2021-07-12
RS61759B9 (sr) 2021-11-30
EP3943490A1 (en) 2022-01-26
KR20170131654A (ko) 2017-11-29
HUE054474T2 (hu) 2021-09-28
US10689345B2 (en) 2020-06-23
AU2016240033B2 (en) 2020-04-16
JP7389856B2 (ja) 2023-11-30
ES2864950T9 (es) 2021-11-18
LT3277677T (lt) 2021-05-25
PL3277677T3 (pl) 2021-08-30
ES2864950T3 (es) 2021-10-14
HRP20210791T1 (hr) 2021-06-25
EP3277677A1 (en) 2018-02-07
KR102578325B1 (ko) 2023-09-15
NZ736450A (en) 2022-04-29
EP3277677B1 (en) 2021-02-24
JP2020143124A (ja) 2020-09-10
US20220251041A1 (en) 2022-08-11
CA2976741C (en) 2023-01-17
CN112707893A (zh) 2021-04-27
MY188957A (en) 2022-01-14
CN107484415A (zh) 2017-12-15
MD3277677T2 (ro) 2021-07-31
DK3277677T3 (da) 2021-05-25
US20200181086A1 (en) 2020-06-11
PT3277677T (pt) 2021-04-20
HRP20210791T2 (hr) 2021-12-10
CO2017011172A2 (es) 2018-01-16
BR112017020900B1 (pt) 2023-02-23
MX2017012566A (es) 2018-01-25
JP2018510183A (ja) 2018-04-12
EP3842427A1 (en) 2021-06-30
EP3277677B9 (en) 2021-07-14
SG11201706542TA (en) 2017-10-30
CY1124170T1 (el) 2022-05-27
CA2976741A1 (en) 2016-10-06
RU2717238C2 (ru) 2020-03-19
US20190284138A1 (en) 2019-09-19
US20180086708A1 (en) 2018-03-29
JP2022123095A (ja) 2022-08-23
IL254721B (en) 2019-12-31
WO2016156816A1 (en) 2016-10-06
US20190322624A1 (en) 2019-10-24
CN112707893B (zh) 2023-10-31
US11390584B2 (en) 2022-07-19
RU2017134901A (ru) 2019-04-30
AU2016240033A1 (en) 2017-11-09
US10343992B2 (en) 2019-07-09
JP7216682B2 (ja) 2023-02-01
IL254721A0 (en) 2017-11-30
JP6708661B2 (ja) 2020-06-10
SI3277677T1 (sl) 2021-08-31
US20190270708A1 (en) 2019-09-05
ZA201705717B (en) 2019-09-25
RU2017134901A3 (enExample) 2019-06-25
US11053198B2 (en) 2021-07-06
HK1245266A1 (zh) 2018-08-24
US11066365B2 (en) 2021-07-20
RS61759B1 (sr) 2021-05-31

Similar Documents

Publication Publication Date Title
CN107484415B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
CN107849013B (zh) 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
EP3197883B1 (en) Novel compounds
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
ES2864948T3 (es) Aparato de colocación de remaches ciegos y dispositivo de procesamiento de remaches ciegos con un aparato de colocación de remaches ciegos
HK40043421B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
HK1245266B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
HK40026813A (zh) 新化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1245266

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant